Paper · 23940356

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.

Hanker AB and 11 others. Proc Natl Acad Sci U S A, 2013. Cited by 162 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Papers, record 23940356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23940356

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.; PubMed
Journal: Proc Natl Acad Sci U S A; PubMed
Year: 2013; PubMed
Publication types: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/23940356/; PubMed
DOI: https://doi.org/10.1073/pnas.1303204110; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3761610/; PubMed
The journal: https://conductscience.org/library/journal-index/7505876; PubMed
Citations, by iCite: 162; iCite
Relative citation ratio, by iCite: 3.82; iCite
Revised in PubMed: 2026-01-28; PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Hanker AB	Ariella B
2	Pfefferle AD	Adam D
3	Balko JM	Justin M
4	Kuba MG	María Gabriela
5	Young CD	Christian D
6	Sánchez V	Violeta
7	Sutton CR	Cammie R
8	Cheng H	Hailing
9	Perou CM	Charles M
10	Zhao JJ	Jean J

1 to 10 of 12Source PubMed

See all 12 authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Combined Chemotherapy Protocols	Major topic
Drug Resistance, Neoplasm	Major topic
Genes, erbB-2	Major topic
Mammary Neoplasms, Experimental	Major topic
Mutation	Major topic
Phosphatidylinositol 3-Kinases	Major topic
Animals
Class I Phosphatidylinositol 3-Kinases
Epithelial-Mesenchymal Transition
Lung Neoplasms
Mice
Mice, Transgenic

Source PubMed

Grants16

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P50CA58223	NCI NIH HHS	United States	P50CA058223	PubMed and NIH	NIH RePORTER
R01 CA080195	NCI NIH HHS	United States	R01CA080195	PubMed and NIH	NIH RePORTER
R01 CA134502	NCI NIH HHS	United States	R01CA134502	PubMed and NIH	NIH RePORTER
R01 CA172461	NCI NIH HHS	United States	R01CA172461	PubMed and NIH	NIH RePORTER
R01 CA138255	NCI NIH HHS	United States	R01CA138255	PubMed and NIH	NIH RePORTER
R01 CA148761	NCI NIH HHS	United States	R01CA148761	PubMed and NIH	NIH RePORTER
P50 CA098131	NCI NIH HHS	United States	P50CA098131	PubMed and NIH	NIH RePORTER
CA138255	NCI NIH HHS	United States	R01CA138255	PubMed and NIH	NIH RePORTER
R01 CA143126	NCI NIH HHS	United States	R01CA143126	PubMed and NIH	NIH RePORTER
CA148761	NCI NIH HHS	United States	R01CA148761	PubMed and NIH	NIH RePORTER

1 to 10 of 16

See all 16 grants

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	22,370,636	Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.	Oncogene	2013	https://conductscience.org/library/papers/22370636	PubMed
2	15,073,130	HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.	Clin Cancer Res	2004	https://conductscience.org/library/papers/15073130	PubMed
3	19,492,080	Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.	PLoS Biol	2009	https://conductscience.org/library/papers/19492080	PubMed
4	22,666,336	Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.	PLoS One	2012	https://conductscience.org/library/papers/22666336	PubMed
5	17,936,563	A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.	Cancer Cell	2007	https://conductscience.org/library/papers/17936563	PubMed
6	22,949,682	Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).	Proc Natl Acad Sci U S A	2012	https://conductscience.org/library/papers/22949682	PubMed
7	17,349,583	Molecular definition of breast tumor heterogeneity.	Cancer Cell	2007	https://conductscience.org/library/papers/17349583	PubMed
8	21,671,017	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.	Breast Cancer Res Treat	2012	https://conductscience.org/library/papers/21671017	PubMed
9	9,831,867	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem Cells	1998	https://conductscience.org/library/papers/9831867	PubMed
10	22,585,995	Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes.	Cancer Discov	2012	https://conductscience.org/library/papers/22585995	PubMed

1 to 10 of 39

See all 39 references

Cited by125

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 162 citations.

PMID	Title	Journal	Year	In Papers	Source
42,714,796	HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects.	Sci China Life Sci	2026	https://conductscience.org/library/papers/42714796	PubMed
42,669,662	PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation.	Signal Transduct Target Ther	2026	https://conductscience.org/library/papers/42669662	PubMed
42,323,696	Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.	Breast Cancer Res	2026	https://conductscience.org/library/papers/42323696	PubMed
41,899,598	Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy.	Cancers (Basel)	2026	https://conductscience.org/library/papers/41899598	PubMed
41,870,284	Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.	Clin Cancer Res	2026	https://conductscience.org/library/papers/41870284	PubMed
41,437,938	Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.	Ther Adv Med Oncol	2025	https://conductscience.org/library/papers/41437938	PubMed
41,404,730	Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis.	Elife	2025	https://conductscience.org/library/papers/41404730	PubMed
40,074,330	Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors.	J Immunother Cancer	2025	https://conductscience.org/library/papers/40074330	PubMed
39,854,662	Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.	J Clin Oncol	2025	https://conductscience.org/library/papers/39854662	PubMed
39,769,140	The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review.	Int J Mol Sci	2024	https://conductscience.org/library/papers/39769140	PubMed

1 to 10 of 125

See all 125 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
PIK3CA	5,290	PubTator's text mining	https://conductscience.org/library/genes/5290	NCBI Gene
PIK3R1	5,295	PubTator's text mining	https://conductscience.org/library/genes/5295	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bank	Accession
GEO	GSE41118

Source GEO

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23940356

GET https://conductscience.org/api/papers/v1/23940356/references?page=2

API reference For AI assistants